Study record
TA-65 lengthens telomeres in a 1-year RCT (Salvador et al., 2016)
Human RCT — telomere-length biomarker endpoint
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 3 — Human RCT — telomere-length / telomerase-activity biomarker endpoint
Record verify: source publication identified; see evidence and limitations
| Design | Randomized, double-blind, placebo-controlled trial (telomere-length biomarker) |
| N | 117 |
| PMID | 26950204 |
| DOI | 10.1089/rej.2015.1793 |
| Citation status | Original publication identity matched by title, author and DOI; relevant full-text sections, results and limitations examined 2026-10-14. |
Five-qualifier claim
| Species / population | 117 relatively healthy CMV-positive adults aged 53–87 enrolled in Barcelona, Spain; 97 completed (52 placebo, 23 low-dose, 22 high-dose). |
| Exposure, route, schedule | Oral TA-65MD: 250 U/day (8 mg active ingredient) or 1000 U/day (32 mg), in cycles of 90 days intake followed by 14 days abstinence across one year. |
| Comparator / duration | Placebo-controlled, double-blind, randomized; 1-year duration. |
| Endpoint / numeric result | In the adjusted multilevel model, the low-dose versus placebo difference in change at 12 months was +530 ± 180 bp (p=0.005). This is not the raw within-arm increase: Table 1 median-length group averages changed +240 bp in low dose and −290 bp in placebo. High-dose between-group changes were not significant. |
| What it did NOT establish | Telomere length is a contested biomarker, not a clinical or lifespan outcome. The unusual dose-response (low dose worked, high dose did not) and the authors' commercial interest in TA-65 both temper interpretation. No healthy-aging or lifespan benefit is established. |
Interventions
Primary reference
https://doi.org/10.1089/rej.2015.1793
Each identifier above was confirmed against the primary record; the citation status names the source and the date. An identifier that could not be confirmed is left empty and named as such in the record, never filled in from a secondary source.